# MTRI catalysts: InMed Pharmaceuticals Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mtri/catalysts

> InMed Pharmaceuticals Inc. (MTRI) has 3 upcoming catalysts. The next is the INM-901 trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for MTRI?

InMed Pharmaceuticals Inc. (MTRI) has 3 upcoming catalysts. The next is the INM-901 trial start, 2027. Press release filed with the SEC (EX-99): ""Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." [Calendar and source filings](https://sec-api.dev/companies/mtri/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001062993-26-001347, https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/exhibit99-1.htm (retrieved 2026-11-12). Last confirmed 2026-03-09. Cite: https://sec-api.dev/companies/mtri/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | InMed Pharmaceuticals Inc. |
| Ticker | MTRI (Nasdaq) |
| SEC CIK | 1728328 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mtri |

## Cash runway

Cash $5.2M as of 2026-03-31; quarterly burn $1.7M; about 9.2 months of runway at that rate (XBRL company facts, accession 0001213900-26-052920).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 30, 2024 | [INM-901 interim data readout](https://sec-api.dev/pdufa/inm-901) | MTRI |  | completed, positive | "July 30, 2024 — we announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease ("AD") study of" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1728328/000121390024098445/ea0219774-10q_inmed.htm)) |
| 2027 | [INM-901 trial start](https://sec-api.dev/pdufa/inm-901) | MTRI |  | scheduled | ""Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/exhibit99-1.htm)) |
| mid-2027 | [MT-001 interim data readout](https://sec-api.dev/pdufa/mt-001) | MTRI |  | scheduled | "Phase 1 clinical trial for MT-001, a monoclonal antibody targeting PACAP, ongoing with initial data expected mid-2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728328/000119312526452706/d183007dex991.htm)) |
| late 2027 | [MT-002 interim data readout](https://sec-api.dev/pdufa/mt-002) | MTRI |  | scheduled | "MT-002, a bispecific antibody targeting both PACAP and CGRP, is on track for regulatory filing in Q1 2027 with initial data expected by year-end 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728328/000119312526452706/d183007dex991.htm)) |

## Drugs

- [INM-901](https://sec-api.dev/pdufa/inm-901): 
- [MT-001](https://sec-api.dev/pdufa/mt-001): 
- [MT-002](https://sec-api.dev/pdufa/mt-002): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mtri/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MTRI catalysts: InMed Pharmaceuticals Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mtri/catalysts

```bibtex
@misc{secapidev_companies_mtri_catalysts_20261116,
  title        = {MTRI catalysts: InMed Pharmaceuticals Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mtri/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mtri_catalysts_20261116","title":"MTRI catalysts: InMed Pharmaceuticals Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mtri/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
